Healthcare facilities are instructed to immediately stop using affected IV solution sets while FDA evaluates the potentially high-risk device issue
The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding certain Baxter Duo-Vent Solution Sets after identifying a potentially serious defect that could allow air to enter a patient’s intravenous (IV) line during infusion.
Although no serious injuries or deaths have been reported, the FDA is advising healthcare facilities to immediately stop using the affected products, quarantine existing inventory, and arrange for their return.
Device use
The Duo-Vent Solution Set is designed to deliver fluids intravenously through a vascular access device and is commonly used in hospitals and other healthcare settings.
Because these devices are frequently used in critically ill patients, maintaining the integrity of the infusion system is essential to prevent potentially life-threatening complications.
Affected products
The alert applies to the following Baxter device:
| Product Code | Description | Affected Lot Numbers |
| 1C8507 | Duo-Vent Solution Set with Male Luer Lock Adapter, 10 drops/mL, 109-inch sterile set | DR26C27062, DR26D14031, DR26E13055 |
The FDA states that Baxter notified customers on June 30 and initiated a customer-level removal of the affected lots.
What is the problem?
According to Baxter, certain affected administration sets may develop air bubbles within the drip chamber and tubing when a pressure cuff is used to pressurize the IV fluid bag, or the tubing is flushed while the clamp is fully open. Under these conditions, air may enter the infusion line.
If an infusion pump equipped with an air-in-line detector is not being used, as may occur during pressure infusions, air could be delivered directly into the patient’s bloodstream.
Potential patient risks
Small amounts of air entering the venous circulation are often absorbed by the lungs without causing injury.
However, the risk increases significantly in patients with certain cardiovascular abnormalities, including Patent foramen ovale (PFO), right-to-left cardiac shunts, and other vascular abnormalities that permit air to bypass pulmonary filtration.
In these patients, air emboli may enter the arterial circulation, potentially resulting in stroke, myocardial ischemia (reduced blood flow to the heart), organ damage, or death.
As of July 15, Baxter reported no serious injuries or deaths associated with this issue.
FDA recommendations
Healthcare providers should immediately identify all affected lots, remove the devices from clinical use, quarantine existing inventory, arrange return and replacement through Baxter or the original distributor, and notify all departments using the affected devices, including nursing, pharmacy, purchasing and risk management.
Distributors should conduct user-level recalls for affected customers.
The FDA notes that it continues to evaluate this issue and will update healthcare providers as additional information becomes available.
MDP safety perspective
This Early Alert illustrates why even seemingly simple medical devices deserve rigorous manufacturing controls and postmarket surveillance.
Unlike sophisticated infusion pumps or implantable devices, IV administration sets are often viewed as low-complexity disposable products. Yet a seemingly minor defect involving trapped air can create a pathway for one of medicine’s most serious infusion-related complications, an air embolism.
Several aspects of this alert deserve attention. First, the reported problem appears to become clinically significant under specific use conditions, particularly pressure-assisted infusions or fully open flushing, highlighting the importance of evaluating devices under realistic clinical scenarios during design validation and risk management.
Second, Baxter’s report notes that patients are at greatest risk when an air-in-line detector is not present, underscoring how device safety frequently depends upon the interaction of multiple products within the clinical system rather than any single device alone.
Finally, this alert serves as a reminder that healthcare facilities should respond promptly to manufacturer notifications, even when no injuries have yet occurred. Early intervention is precisely what FDA Early Alerts are intended to achieve: identifying potential hazards before they become patient injuries.
Hospitals should use this opportunity to review inventory controls, recall procedures and communication pathways to ensure affected devices are rapidly removed from service whenever safety alerts are issued.
Links
Read the FDA Early Alert here.
FDA Closes Moringa Salmonella Outbreak Investigation
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
Class I Recall for Bolton Medical RelayPro Thoracic Stent Graft
FDA Issues Class I Recall for RelayPro Thoracic Stent Graft Following Three Patient DeathsDeployment failure during aortic repair may require emergency open surgery The U.S. Food and Drug Administration (FDA) has issued a Class I recall for certain RelayPro Thoracic...
Arrow Corrects Kits With Recalled Injectable Medications
FDA Classifies Field Correction As Class I Recall Due to Risk of Serious Injury The U.S. Food and Drug Administration (FDA) has classified a correction issued by Arrow International, a subsidiary of Teleflex, as a Class I recall after certain convenience kits were...
Casgevy Gene Therapy Expanded to 2-Year-Old Children
FDA Expands Casgevy Gene Therapy Approval to Children as Young as 2 with Sickle Cell DiseaseFirst CRISPR-based gene therapy approved for young children with sickle cell disease The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Casgevy...
FDA Issues Early Alert for Resmed Astral Ventilators
Resmed VentilatorPatients should continue using devices unless instructed otherwise by their healthcare provider The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain Resmed Astral 100 and...
